Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

[1]  T. Julian,et al.  Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial , 2016, The Lancet.

[2]  E. Hwang,et al.  Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. , 2015, Journal of the National Cancer Institute.

[3]  S. Pinder,et al.  Addressing overtreatment of screen detected DCIS; the LORIS trial. , 2015, European journal of cancer.

[4]  S. Hankinson,et al.  Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers , 2015, Steroids.

[5]  V. Beral,et al.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. , 2015, Lancet.

[6]  V. Beral,et al.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies , 2015, The Lancet.

[7]  J. Cuzick,et al.  Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial , 2015, The Lancet. Oncology.

[8]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[9]  R. Kay.  The Analysis of Survival Data , 2012 .

[10]  J. Thigpen.  Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24 , 2012 .

[11]  S. Duffy,et al.  Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. , 2011, Journal of the National Cancer Institute.

[12]  J. Cuzick,et al.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.

[13]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[14]  G. Kimmick.  Faculty Opinions recommendation of Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010 .

[15]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[16]  S. Gruber,et al.  Use of hormone replacement therapy and the risk of colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Ghersi,et al.  Post-operative radiotherapy for ductal carcinoma in situ of the breast. , 2009, The Cochrane database of systematic reviews.

[18]  Jack Cuzick,et al.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Dewar,et al.  Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project , 2007, British Journal of Cancer.

[20]  T. Powles,et al.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.

[21]  K. Mokbel,et al.  Heterogeneity of ductal carcinoma in situ and its effects on management. , 2006, The Lancet. Oncology.

[22]  J. Cuzick,et al.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.

[23]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[24]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[25]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[26]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[27]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[28]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[29]  M. Lagios.  Heterogeneity of ductal carcinoma in situ of the breast , 1993, Journal of cellular biochemistry. Supplement.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[31]  D.,et al.  Regression Models and Life-Tables , 2022 .